Research Topics
Genomes and Genes | Takeo NakanishiSummaryAffiliation: University of Maryland Country: USA Publications
| Collaborators
|
Detail Information
Publications
Drug transporters as targets for cancer chemotherapyTakeo Nakanishi
The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland at Baltimore, Baltimore, MD 21201, USA
Cancer Genomics Proteomics 4:241-54. 2007..This review will focus on the role of drug transporters in the adaptation and growth of tumors and in their potential usefulness as therapeutic targets in cancer...- Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usageTakeo Nakanishi
The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center Departments of Medicine and Microbiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
Cancer Res 66:5007-11. 2006..The exon 1 variation we observe suggests that alternative promoters of the BCRP gene exist... - Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patientsTakeo Nakanishi
Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Clin Cancer Res 9:3320-8. 2003..CONCLUSIONS: These results suggest that unlike P-gp, BCRP may play a role in leukemia cellular resistance to flavopiridol. No mutations at codon 482 were observed in BCRP mRNA in this group of patients... 
Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestineKarthika Natarajan
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
Biochim Biophys Acta 1809:295-305. 2011..Furthermore, Bcrp1 E1b mRNA expression is regulated by binding of p-CREB to its cis site on the mouse E1b promoter region...
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemiasKen Shiozawa
Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Clin Cancer Res 15:1698-707. 2009..In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias...- Thapsigargin resistance in human prostate cancer cellsChidambaram Natesa Velalar
Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
Cancer 107:649-59. 2006.... - Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expressionTakeo Nakanishi
Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, 21201, USA
Blood 108:678-84. 2006..These studies show that BCRP causes measurable imatinib resistance, but this effect is attenuated by imatinib-mediated inhibition of BCR-ABL, which in turn downregulates overall BCRP levels posttranscriptionally via the PI3K-Akt pathway... - A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cellsLeslie M Tompkins
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States
Biochem Pharmacol 80:1754-61. 2010.... - Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitorsXuetao Fan
The Program in Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, Departments of Medicine, Pathology and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA
Biochem Pharmacol 80:811-8. 2010..Our findings indicate that LAT1 expression is increased in human ovarian cancer cell lines; LAT1 may be a target for combination therapy with anti-proliferative aminopeptidase inhibitors to combat ovarian cancer... - Impact of breast cancer resistance protein on cancer treatment outcomesDouglas D Ross
University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, MD, USA
Methods Mol Biol 596:251-90. 2010.... - Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevisTakeo Nakanishi
Greenebaum Cancer Center, University of Maryland School of Medicine, Room 9 045, Bressler Research Building, 655 W Baltimore St, Baltimore, MD 21201, USA
Mol Pharmacol 64:1452-62. 2003..We conclude that the X. laevis oocyte heterologous expression system is a valid and effective means of studying BCRP function and substrate specificity... - The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cellsYuexing Zhang
Greenebaum Cancer Center and Departments of Pathology and Pharmacology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 102:9890-5. 2005..These findings suggest that Ebp1 is a previously unrecognized therapeutic target for treatment of hormone refractory prostate cancer... - Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trialJudith E Karp
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 2120, USA
Clin Cancer Res 9:307-15. 2003..trigger apoptosis in fresh acute leukemia; and (b). recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C)... - The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cellsYingqiu Xie
Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore 21201, USA
J Biol Chem 283:3349-56. 2008..These findings may provide a potential therapeutic approach by disrupting Pim-1 signaling to reverse BCRP-mediated multidrug resistance... - Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cellsRachael Strong
Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland, USA
J Proteome Res 5:2389-95. 2006..Eleven mitochondrial proteins were found with abundances altered more than 2-fold. Transcription was evaluated for two of these, using quantitative RT-PCR. Implications of the changes are considered with respect to drug resistance... - The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with hemePartha Krishnamurthy
Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
J Biol Chem 279:24218-25. 2004..Our findings have implications for the survival of stem cells and tumor cells in hypoxic environments... - Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survivalAttaya Suvannasankha
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Br J Haematol 127:392-8. 2004..0374) in this small patient population. Poor correlations between mRNA, protein and function indicate the complex biology of BCRP in adult ALL, and the possible correlation of BCRP expression with DFS should be studied in larger series... - Transport of D-serine via the amino acid transporter ATB(0,+) expressed in the colonTakahiro Hatanaka
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
Biochem Biophys Res Commun 291:291-5. 2002..Expression is most predominant in the colon where the transporter is localized to the luminal membrane of colonocytes, making this transporter uniquely suitable for absorption of bacteria-derived D-serine...